The company plans to submit a Biologics Licence Application to the US Food and Drug Administration later in 2025 for its DMD ...

Orca Bio’s T-cell immunotherapy candidate for blood cancers has more than doubled the number of patients surviving free of ...

The FDA has removed the clinical hold on vTv Therapeutics' cadisegliatin clinical programme, including the Phase III CATT1 trial for T1D.

Zealand Pharma has concluded enrolment for its global, randomised Phase IIb ZUPREME-1 trial, assessing petrelintide.

AstraZeneca acquired the hypoparathyroidism therapy eneboparatide as part of a buyout of Amolyt Pharma in July 2024.